glp-1 pill form Why Weight-Loss Drugs Are Hard to Make into Pills GLP-1 Drugs | Scientific American

Based on this review, evidence from head-to-head and insulin-comparator trials demonstrates that dual GIP/GLP-1 co-agonism consistently overcomes metabolic plateaus that result from single-pathway therapy, producing superior glycated hemoglobin reduction, bariatric-level weight loss (up to 25.3%), and robust macrovascular and heart failure protection, including a 38% reduction in composite cardiovascular risk among patients with heart failure with preserved ejection fraction (HFpEF)

Considerations regarding adverse effects and contraindications for different drug classes are provided to help guide treatment decision-making when considering pharmacotherapy for weight management in patients with obesity.

Weight loss pills and a growing number of ways to buy the drugs could make them easier to access.

In late April 2025, the FDA issued a key update regarding the use of compounded GLP-1 receptor agonists like semaglutide and tirzepatide

Purpose Chronic kidney disease (CKD) is one of the most common complications of type 2 diabetes (T2D), and CKD-related disability and mortality are increasing despite the recent advances in diabetes management

Those numbers are particularly pronounced in states where the obesity rate is higher